Research progress in the regulation of programmed cell death 1 receptor and its ligand pathway and the strategies against tumor drug resistance
Department of Clinical Laboratory, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China；Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Abstract：The overexpression of programmed cell death 1 receptor (PD-1) on the surface of T cells and programmed cell death 1 ligand 1 (PD-L1) secreted by tumor cells in tumor tissue inhibits the cellular immune response to a certain degree, so that the growth of tumor cells can escape the surveillance and clearance of the immune system. PD-1/PD-L1 inhibitors are specific protein antibodies designed for the expression of PD-1 or PD-L1, which can prevent the interaction between PD-1 and PD-L1 on tumor cells, thus partially restore T cell function and enhance tumor cell killing by T cells. However, because of the increasingly prominent drug resistance of PD-1/PD-L1 inhibitors in clinical applications, their efficacy cannot be sustained or even there were non-response to drugs in some patients. Recent studies have found that the expression of PD-1 and PD-L1 is regulated by many immune factors, and the transport and degra- dation processes of PD-L1 are also affected by many factors, such as glycosylation, phosphorylation, ubiquitination, and so on. The researches on the regulatory factors that may interfere in the PD-1/PD-L1 pathway will help to develop new treatment strategies to overcome drug resistance of PD-1/PD-L1 inhibitors in tumor, thereby improving the efficacy of tumor immunotherapy.
谢阿青，王琳. 程序性细胞死亡1受体及其配体通路的调控与肿瘤耐药对策的研究进展[J]. 药物不良反应杂志, 2020, 22(4): 257-261.
Xie Aqing, Wang Lin. Research progress in the regulation of programmed cell death 1 receptor and its ligand pathway and the strategies against tumor drug resistance. Adverse Drug Reactions Journal, 2020, 22(4): 257-261.
